Zimmer Biomet (NYSE:ZBH – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at Argus in a report released on Thursday, Benzinga reports. They presently have a $125.00 price target on the medical equipment provider’s stock. Argus‘s price objective would indicate a potential upside of 26.48% from the company’s current price.
Several other research analysts also recently commented on ZBH. UBS Group reissued a “buy” rating and issued a $120.00 price target on shares of Zimmer Biomet in a report on Thursday, August 6th. BMO Capital Markets reissued a “market perform” rating on shares of Zimmer Biomet in a report on Monday, September 28th. Zacks Research raised shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 25th. Robert W. Baird set a $104.00 price target on shares of Zimmer Biomet in a report on Thursday, August 6th. Finally, Barclays raised shares of Zimmer Biomet to a “hold” rating in a report on Wednesday, October 7th. Seven investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $104.47.
Read Our Latest Stock Analysis on Zimmer Biomet
Zimmer Biomet Stock Performance
Shares of Zimmer Biomet stock traded up $3.97 during trading hours on Thursday, reaching $98.83. The company had a trading volume of 1,539,445 shares, compared to its average volume of 2,225,832. Zimmer Biomet has a one year low of $79.12 and a one year high of $104.15. The business has a fifty day simple moving average of $95.18 and a 200 day simple moving average of $91.41. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. The firm has a market cap of $18.85 billion, a PE ratio of 24.05, a price-to-earnings-growth ratio of 1.81 and a beta of 0.49.
Zimmer Biomet (NYSE:ZBH – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The firm had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same period last year, the company earned $2.07 earnings per share. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, analysts anticipate that Zimmer Biomet will post 8.54 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, insider Chad F. Phipps sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the transaction, the insider owned 65,231 shares in the company, valued at $6,415,468.85. This represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kevin R. Thornal sold 5,691 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.28% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the stock. Tacita Capital Inc purchased a new position in shares of Zimmer Biomet during the 2nd quarter worth approximately $26,000. Ancora Advisors LLC purchased a new position in shares of Zimmer Biomet during the 2nd quarter worth approximately $29,000. Elevation Wealth Partners LLC grew its holdings in shares of Zimmer Biomet by 145.9% during the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 229 shares during the period. Cassaday & Co Wealth Management LLC purchased a new position in shares of Zimmer Biomet during the 1st quarter worth approximately $44,000. Finally, Parvin Asset Management LLC purchased a new position in shares of Zimmer Biomet during the 2nd quarter worth approximately $47,000. 88.89% of the stock is owned by hedge funds and other institutional investors.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.
The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.
Read More
- Five stocks we like better than Zimmer Biomet
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
